Scott Kasner talks to Eivind Berge about the GORE REDUCE trial at ESOC 2017 in Prague. Established superiority of PFO closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new brain infarct.
Content produced and shared with kind authorisation of the European Stroke Organisation (ESO) and the European Stroke Organisation Conference (ESOC 2017).
Share this Video
Related Videos In Stroke
Hariklia Proios, Stroke Alliance for Europe (SAFE): Presidential Update
The Stroke Alliance for Europe (SAFE) is a non-profit-making organisation that represents a range of patient groups from across Europe. Their mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education. touchNEUROLOGY caught up with the SAFE President, Prof. Hariklia (Harriet) Proios, to discuss the […]
Martin Bretzner, ESOC 2022: Brain-age biomarkers to predict post-stroke recovery
Brain-age biomarkers can be used to predict post-stroke recovery. Dr Martin Bretzner (Lille Neuroscience & Cognition Research Centre, Lille University Hospital, Lille, France) discusses the results of a study using radiomics, an emerging image-quantifying technology to assess ‘brain-age’ biomarkers. The study investigates how relative brain age, rather than chronological age, can enhance stroke surveillance and […]
Miquel Lledós, ESOC 2022: The influence of gut microbiome on ischaemic stroke risk and outcome
The composition of the gut microbiome is a modifiable factor associated with the risk of ischaemic stroke and post-stroke neurological outcome. Dr Miquel Lledós (Stroke Pharmacogenomics and Genetics Laboratory, Sant Pau Research Institute, Barcelona, Spain) discusses the outcome of a study using faecal samples to demonstrate the influence of the gut microbiome on ischaemic stroke […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!